Emergent Bio Jumps as ACAM2000 Gets FDA Approval for Mpox (2)

Emergent BioSolutions shares jump 20% in premarket trading after the company said the US FDA approved the expansion of the indication for ACAM2000 to include prevention of mpox disease in individuals determined to be at high risk.

• Vaccine was first approved by the FDA in 2007 for active immunization for the prevention of smallpox disease in people found to be at high risk
• NOTE: Emergent Leads Mpox-Tied Stock Gains as Investors Await Approval

(Updates shares in first paragraph.)

--With assistance from Joel Leon.

To contact the reporter on this story:
Greg Chang in San Francisco at gchang1@bloomberg.net

To contact the editors ...